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Objectives: Nonadherence to prescription medications has been shown to be significantly 
influenced by three key medication-specific beliefs: patients’ perceived need for the prescribed 
medication, their concerns about the prescribed medication, and perceived medication 
affordability. Structural equation modeling was used to test the predictors of these three proximal 
determinants of medication adherence using the proximal–distal continuum of adherence drivers 
as the organizing conceptual framework.
Methods: In Spring 2008, survey participants were selected from the Harris Interactive Chronic Illness 
Panel, an internet-based panel of hundreds of thousands of adults with chronic disease. Respondents 
were eligible for the survey if they were aged 40 years and older, resided in the US, and reported hav-
ing at least one of six chronic diseases: asthma, diabetes, hyperlipidemia, hypertension, osteoporosis, 
or other cardiovascular disease. A final sample size of 1072 was achieved. The proximal medication 
beliefs were measured by three multi-item scales: perceived need for medications, perceived medi-
cation concerns, and perceived medication affordability. The intermediate sociomedical beliefs and 
skills included four multi-item scales: perceived disease severity, knowledge about the prescribed 
medication, perceived immunity to side effects, and perceived value of nutraceuticals. Generic health 
beliefs and skills consisted of patient engagement in their care, health information-seeking tendencies, 
internal health locus of control, a single-item measure of self-rated health, and general mental health. 
Structural equation modeling was used to model proximal–distal continuum of adherence drivers.
Results: The average age was 58 years (range = 40–90 years), and 65% were female and 89% 
were white. Forty-one percent had at least a four-year college education, and just under half 
(45%) had an annual income of $50,000 or more. Hypertension and hyperlipidemia were each 
reported by about a quarter of respondents (24% and 23%, respectively). A smaller percentage 
of respondents had osteoporosis (17%), diabetes (15%), asthma (13%), or other cardiovascular 
disease (8%). Three independent variables were significantly associated with the three proximal 
adherence drivers: perceived disease severity, knowledge about the medication, and perceived 
value of nutraceuticals. Both perceived immunity to side effects and patient engagement was sig-
nificantly associated with perceived need for medications and perceived medication concerns.
Conclusion: Testing the proximal–distal continuum of adherence drivers shed light on spe-
cific areas where adherence dialogue and enhancement should focus. Our results can help to 
inform the design of future adherence interventions as well as the content of patient education 
materials and adherence reminder letters. For long-term medication adherence, patients need 
to autonomously and intrinsically commit to therapy and that, in turn, is more likely to occur 
if they are both informed (disease and medication knowledge and rationale, disease severity, 
consequences of nonadherence, and side effects) and motivated (engaged in their care, perceive 
a need for medication, and believe the benefits outweigh the risks).
Keywords: compliance, prescription medications, medication beliefs, treatment beliefs
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Introduction
Over the past 40 years, numerous conceptual models have 
been proposed to explain medication nonadherence.1 A short 
listing of models that have been tested in relation to medica-
tion adherence include the Health Belief Model,2 the Theory 
of Reasoned Action,3 the Theory of Planned Behavior,4 
the Transtheoretical Model,5 the Necessity-Concerns 
Framework,6 the Information-Motivation-Behavioral Skills 
model,7 and the Information-Motivation-Strategy model.8 
Most of these frameworks belong to the family of models sub-
sumed under social-cognitive theory,1 and these models have 
incrementally built on the conceptual and empirical learning 
of one another. At the heart of all of these frameworks, as well 
as others, are two guiding assumptions: (1) individuals make 
decisions about prescription medications (ie, patients do not 
passively and reflexively obey physician recommendations 
about prescription medications); and (2) medication adher-
ence is influenced by an array of patient beliefs, attitudes, 
skills, and experiences.
In 2009, the Proximal–Distal Continuum of Adherence 
Drivers model was proposed.9 In the proximal–distal con-
tinuum, it was asserted that some adherence determinants 
are nearer or closer to patients’ medication-taking decisions 
(proximal) while others are more removed (further from) 
patients’ adherence decisions. The aim of the proximal–
distal continuum was to organize the numerous hypothesized 
medication adherence drivers along an etiological continuum 
of determinants ranging from those shown to have strong 
empirical relationships with adherence (proximal drivers) to 
those with weaker relationships (distal drivers). In short, the 
proximal–distal continuum consists of an etiological hierar-
chy of hypothesized adherence drivers in order to account for 
medication adherence in a multifactorial manner.
The proximal–distal continuum is based upon three fun-
damental tenets. First, an adherent “personality” does not 
exist – the same individual can be adherent to one medica-
tion, not fill a second medication prescription, decide to stop 
taking a third medicine without the advice of their provider, 
and be careless taking a fourth medication.9 A growing 
body of research has demonstrated that individual patients 
have different adherence patterns and levels for assorted 
medications, both within a therapeutic class10–12 as well as 
across therapeutic areas.13–16 Intraindividual variability in 
medication taking occurs because patients have different 
beliefs about different prescribed medications and their 
attendant diagnosed conditions. Second, patient beliefs, 
skills, and experiences that influence medication adherence 
can be either specific to a prescribed medication or disease 
or they can be generic in nature (ie, nonspecific to a pre-
scribed medication or disease). In general, patient beliefs, 
skills, and experiences specific to a prescribed medication 
or disease tend to be more predictive of adherence than 
generic psychosocial beliefs and skills.9,17–21 Third, for 
many patients, a new diagnosis and the attendant prescribed 
therapy represents uncertainty and is a threat to the status 
quo.22 The short-term benefits of prescription-medication 
therapy can seem intangible to patients, especially to those 
with asymptomatic chronic disease. The long-term benefits 
of prescription medications are probabilistic and can be 
so distant in the future that patients may heavily discount 
them. Viewed through the uncertainty lens, nonadherence 
can make sense from the patient perspective because tak-
ing prescription medications represents a risky prospect 
in the short term (short-term financial, psychological, and 
opportunity costs, and risk of side effects) with uncertain 
long-term benefits (probabilistic reductions in mortality, 
morbidity, and complications) compared to the status quo 
(health as it is).23
At the proximal end of the continuum are patients’ beliefs 
about the prescribed medication (Figure 1). Research over 
the past 20 years has consistently demonstrated that patients’ 
beliefs about a prescribed medication are potent predictors 
of medication adherence. Next, etiologically, are patients’ 
sociomedical and disease-related beliefs, skills, and experi-
ences which are hypothesized to be direct determinants of 
patients’ proximal medication beliefs. Patients’ generic 
beliefs, skills, and experiences are hypothesized to directly 
influence the disease-related and sociomedical beliefs. 
Finally, the most distal variables encompass demographic 
characteristics. Meta-analytic research has demonstrated 
weak associations between sociodemographic characteristics 
and adherence.24
A large body of research has provided evidence 
about the relative influence of the myriad adherence 
drivers potentially subsumed under the proximal–distal 
 continuum. The vast majority of these studies have 
examined medication adherence as the outcome variable. 
However, few studies have modeled the determinants of 
proximal medication beliefs – beliefs demonstrated by 
past research to be powerful predictors of medication 
adherence.  Nonadherence to prescription medications 
has been shown to be significantly influenced by three 
key medication-specific beliefs: patients’ perceived need 
for the prescribed medication,9,18,19,25–37 their  concerns about 
the prescribed medication,9,18,19,26,29,30,33,34,38–47 and perceived 
medication affordability.9,48–55 We used  structural  equation 
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 modeling (SEM) to test the predictors of these three 
 proximal determinants of medication adherence. The goal 
of testing the proximal–distal continuum was to shed light 
on the origins of the three key proximal  medication beliefs. 
This information can contribute insights as to how future 
adherence interventions may be made more efficacious by 
identifying underlying mechanisms influencing perceived 





As described in detail elsewhere,9 in Spring 2008, survey 
participants were selected from the Harris Interactive 
Chronic Illness Panel, an internet-based panel of hundreds 
of thousands of adults with chronic disease. Respondents 
were eligible for the survey if they were aged 40 years and 
older, resided in the US, and reported having at least one of 
six chronic diseases prevalent among US adults: asthma, 
diabetes, hyperlipidemia, hypertension, osteoporosis, or other 
cardiovascular disease (CVD) (eg, angina, myocardial infarc-
tion, congestive heart failure). The six chronic diseases reflect 
a mix of symptomatic and asymptomatic conditions. They 
are some of the most highly prevalent conditions in the US56 
and are associated with a significant clinical and economic 
burden for the US health care system.57 If eligible respondents 
reported more than one of the six target conditions, one was 
randomly selected as the index (study) disease. Panel mem-
bers responding to an e-mail invitation were instructed to read 
the informed consent form and click on yes if they agreed to 
participate. The protocol for the survey was approved by the 
Essex Internal Review Board. A 26.5% survey contact rate 
(per standards recommended by the American Association 
for Public Opinion Research)58 was achieved. A total of 1072 
adults completed the survey.
Survey content
The proximal, intermediate, and distal variables were all 
collected during a single survey administration. The proxi-
mal medication beliefs were measured by three multi-item 
scales: perceived need for medications (k = 12, Cronbach’s 
alpha = 0.96, illustrative item: “I am convinced of the 
importance of my prescription medication.”);9 perceived 
medication concerns (k = 10, Cronbach’s alpha = 0.90 items, 
illustrative item: “I worry that my prescription medication 
will do more harm than good to me.”);9 and perceived 
medication affordability (k = 7, Cronbach’s alpha = 0.97, 
illustrative item “I feel financially burdened by my out-of-
pocket expenses for my prescription medication.”).9 The 
intermediate disease-related and sociomedical beliefs and 
skills included four multi-item scales: perceived disease 
severity (k = 3, Cronbach’s alpha = 0.76, illustrative item: 
“I think that my condition is severe.”); knowledge about 
the index medication (k = 9, Cronbach’s alpha = 0.92, 
illustrative item: “I understand exactly what the medication 
prescribed for me will do for me.”); perceived immunity 
to side effects (k = 3, Cronbach’s alpha = 0.90, illustrative 
item: “My chances of experiencing negative side effects 
from a prescription drug are high.”); and perceived value 
of nutraceuticals (ie, vitamins, minerals, and supplements) 
(k = 7, Cronbach’s alpha = 0.92, illustrative item: “For me 
personally, I believe that vitamin, mineral, and herbal supple-
ments can achieve better health results than prescription 
drugs can.”). Generic health beliefs and skills were measured 


















































Figure 1 The proximal–distal continuum of adherence drivers.
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alpha = 0.97, illustrative item “My doctor and I have a real 
partnership in my health care.”); health information-seeking 
tendencies (k = 5, Cronbach’s alpha = 0.91, illustrative item: 
“I actively seek out information on my illnesses.”); internal 
health locus of control using Wallston’s measure (k = 10, 
Cronbach’s alpha = 0.89);59 general mental health using the 
Mental Health Inventory (k = 5, Cronbach’s alpha = 0.88);60 
and a single-item measure of self-rated health (the “excel-
lent-to-poor” item from the Medical Outcomes Study [MOS] 
Short-Form Health Survey [SF-36]).60 Evidence of the valid-
ity of these measures vis á vis the criterion of medication 
adherence has been previously published.9,61–64 With the 
exception of the Mental Health Inventory (a six-point scale 
ranging from “all of the time” to “none of the time”), health 
locus of control (a six-point scale ranging from “strongly 
disagree” to “strongly agree”), and the “excellent-to-poor” 
item (excellent, very good, good, fair, or poor), all items 
used a six-point categorical rating scale ranging from “agree 
completely” to “disagree completely.” Each multi-item scale 
was computed using Likert’s method65 of summated ratings 
in which each item is equally weighted and raw item scores 
are summed into a scale score. All scale scores were linearly 
transformed to a 0–100 metric, with 100 representing the 
most favorable belief or state, 0 the least favorable, and 
scores in between representing the percentage of the total 
possible score.
Demographic variables were included in the model. 
Age was measured as a continuous variable. Gender and 
race were coded as 1 = female vs 0 = male and 1 = white vs 
0 = nonwhite, respectively. Education was measured as a 
six-level interval variable with higher values indicating 
higher education. Income was measured with an 11-level 
interval variable with higher values indicating higher 
income. Each disease indicator was coded as 1 = present vs 
0 = not present with hypertension selected as the reference 




Logistic regression was used to assess differences between 
Chronic Illness Panel members with valid e-mail addresses 
who did and did not respond to the survey invitation 
(ie, survey noncontact bias per standards recommended by 
the American Association for Public Opinion Research).58 
Independent variables for the logistic regression were age, 
gender, race, education, income, and geographic region of 
residence.
Structural equation modeling (SEM)
SEM was used in this analysis because some variables were 
both endogenous and exogenous, and traditional multivariate 
regression would not efficiently test the path relationships 
in one model. Twelve equations (three equations with the 
proximal beliefs as dependent variables, four equations with 
the intermediate beliefs and skills as dependent variables, 
and five equations with the generic beliefs, states, and skills 
as the dependent variables) were specified to represent the 
hypothesized relationships among the variables, which were 
treated as measured indicators of respondents’ beliefs, states, 
and skills (see Figure 1). A single multivariate path model 
of these structural equations66–69 was estimated by modeling 
the covariance matrix among the observed variables. As 
shown in Figure 1, the three proximal beliefs were speci-
fied to be associated with the intermediate, disease-related 
beliefs and skills, which in turn were associated with the 
distal generic beliefs and skills, and in turn with demographic 
characteristics.
SEM model fitting was performed in two steps. The first 
step was the execution of a full model to include all vari-
ables specified in the proximal–distal continuum (Figure 1). 
The final model, presented in Tables 2–4, includes only 
statistically-significant variables. Statistical significance, 
goodness-of-fit indices, and modification indices were used 
to guide the final model.
All available data were used in the analysis and were 
used as input into Mplus© software (version 6.1; Muthén 
and Muthén, Los Angeles, CA).70 Full information maxi-
mum likelihood with the Mplus MLR estimator was used 
to estimate path coefficients and standard errors robust 
to  nonnormality. The chi-square test and three fit indices 
(comparative fit index [CFI], root mean square error of 
approximation [RMSEA], and the standardized root mean 
square residual [SRMR]) provided an assessment of model 
fit. Good model fit was identified with chi-square ratio , 3.0, 
CFI . 0.95, RMSEA , 0.05, and SRMR , 0.08.71 
Correlated error terms were freely estimated within each 
domain (generic beliefs, intermediate beliefs, and proximal 
beliefs). Mplus uses model modification indices to determine 
what parameters should be added to the model to improve 
model fit. Modification indices are chi-square statistics with 
one degree of freedom for the fixed and constrained param-
eters in a structural equation model. They estimate the change 
in the improvement in the likelihood-ratio chi-square statistic 
for the model if the corresponding parameter is respecified 
as a free parameter. Modifications that improve model fit 
are regarded as potential changes that can be made to the 
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SEM model. The hypothesized relationships were tested 
based on their statistical significances of path coefficients.
Results
Survey noncontact
A 26.5% contact rate was achieved. Compared to those who 
were invited but did not respond to the survey, those suc-
cessfully contacted were more likely to be age 55 and older, 
white, and college educated.9
Sample characteristics
As shown in Table 1, the average age of respondents was 
58 years (range = 40–90 years), and 65% were female and 
89% were white. Forty-one percent had at least a four-year 
college education and just under half (45%) had an annual 
income of $50,000 or more. Hypertension and hyperlipidemia 
were each reported by about a quarter of respondents (24% 
and 23%, respectively). A smaller percentage of respondents 
had osteoporosis (17%), diabetes (15%), asthma (13%), or 
other CVD (8%). A majority of the samples rated their health 
as good (39.1%) or fair (28.8%).
Results of SEM
Table 2 presents the standardized path coefficients from the 
SEM model for the proximal treatment beliefs. Goodness 
of fit indices showed good model fit with CFI = 0.973, 
RMSEA = 0.031 and SRMR = 0.032. The chi-square test 
was statistically significant (chi-square = 248, df = 121, 
P , 0.0001), reflecting a relatively good model fit72 given the 
sample size and deviations from multivariate normality.73–75 
The model fit was much improved compared to the baseline 
full model (chi-square = 299, df = 24, RMSEA = 0.104) 
and an alternative model without considering modifications 
(chi-square = 324, df = 109, RMSEA = 0.043).
Greater perceived need for medications was related to 
greater perceived disease severity (β = 0.480), less value 
placed on nutraceuticals (β = -0.249), more knowledge 
about the index medication (β = 0.244), greater patient 
engagement in their care (β = 0.137), more perceived 
immunity to side effects (β = 0.119), and less information 
seeking (β = -0.090). In addition, age was positively related 
to perceived need for medications. Compared to patients 
with hypertension, those with dyslipidemia, osteoporosis, 
or other CVD perceived less need for the index medication. 
Over two-thirds (68.3%) of the variation in perceived need 
for medications was explained by these eight significant 
predictors.
Fewer medication concerns were associated with more 
perceived immunity to side effects (β = 0.353), less value 
placed on nutraceuticals (β = -0.318), more knowledge about 
the index medication (β = 0.164), greater patient engage-
ment in their care (β = 0.125), less information seeking 
(β = -0.084), less perceived disease severity (β = -0.078), 
and less of an internal locus of control (β = -0.051). As 
age increased, medication concerns decreased. Compared 
to patients with hypertension, those with dyslipidemia 
or osteoporosis had more medication concerns. One-half 
(50.9%) of the variation in perceived medication concerns 
was explained by these nine significant predictors.
Better medication affordability was related to less 
perceived disease severity (β = -0.233), greater income 
Table 1 Sociodemographic characteristics
Sociodemographic characteristic N = 1072
N %
Mean age (±SD) 58.3 (10.4)
Median age (±IQR) 58.0 (17.0)














Less than high school 
High school graduate 
Some college but no degree 
Bachelor’s degree 
Some graduate school but no degree 


















































































Abbreviations: SD, standard deviation; IQR, interquartile range.
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(β = 0.231), less value placed on nutraceuticals (β = -0.222), 
older age (β = 0.166), better self-rated health (β = 0.136), bet-
ter mental health (β = 0.101), and more knowledge about the 
index medication (β = 0.082). Females found medications to 
be less affordable, while education was positively related to 
perceived medication affordability. One-third (34.0%) of the 
variation in perceived medication affordability was explained 
by these nine significant predictors.
The four intermediate beliefs were then modeled as 
dependent variables (Table 3). Greater perceived disease 
severity was related to worse self-rated health (β = -0.262), 
greater patient engagement in their care (β = 0.254),  greater 
information seeking (β = 0.122), and worse mental health 
(β = -0.112). As education increased, perceptions of dis-
ease severity decreased. Compared to patients with hyper-
tension, those with asthma or osteoporosis perceived their 
diseases to be less severe, while those with other CVD and 
diabetes perceived their conditions to be more severe. One-
quarter (25.1%) of the variation in perceived disease severity 
was explained by these six significant predictors.
Greater knowledge about the index medication was 
related to greater patient engagement in their care (β = 0.521), 
greater information-seeking tendencies (β = 0.325), more of 
an internal locus of control (β = 0.062), and better mental 
health (β = 0.047). Close to one-half (47.7%) of the variation 
in knowledge about the index medication was explained by 
these four predictors.
Greater perceived immunity to side effects was associated 
with greater patient engagement in their care (β = 0.259), 
less information-seeking tendencies (β = –0.242), and bet-
ter mental health (β = 0.119). Men felt more immune to 
side effects. As education increased, perceived immunity 
to side effects increased. Fifteen percent of the variation in 
perceived immunity to side effects was explained by these 
five predictors.
More value placed on nutraceuticals was associated 
with less patient engagement in care (β = -0.415), a greater 
internal locus of control (β = 0.209), greater information-
seeking tendencies (β = 0.126), and better self-rated health 
(β = 0.100). Younger persons, nonwhites, and respondents 
with osteoporosis or asthma placed greater value on nutra-
ceuticals compared to those with hypertension. As both 
education and income increased, value placed on nutraceu-
ticals decreased. Over one-quarter (28.6%) of the variation 
in perceived value of nutraceuticals was explained by these 
predictors.




Perceived need for  
medications




Standardized β SE Standardized β SE Standardized β SE
Perceived disease severity 0.480‡ 0.021 -0.078± 0.026 -0.233‡ 0.030
Patient knowledge 0.244‡ 0.031 0.164‡ 0.032 0.082± 0.029
Perceived side-effect immunity 0.119‡ 0.023 0.353‡ 0.024 NS NS
Perceived value of nutraceuticals -0.249‡ 0.025 -0.318‡ 0.030 -0.222‡ 0.029
Patient engagement 0.137‡ 0.027 0.125‡ 0.032 NS NS
Information seeking -0.090‡ 0.021 -0.084± 0.027 NS NS
Internal health locus of control NS NS -0.051* 0.021 NS NS
Self-rated health NS NS NS NS 0.136‡ 0.032
Mental health NS NS NS NS 0.101± 0.031
Age 0.065‡ 0.018 0.094‡ 0.023 0.166‡ 0.026
Female NS NS NS NS -0.072± 0.026
White race NS NS NS NS NS NS
Education NS NS NS NS 0.057* 0.028
Income NS NS NS NS 0.231‡ 0.031
Asthma NS NS NS NS NS NS
Diabetes NS NS NS NS NS NS
Lipid -0.059‡ 0.018 -0.053* 0.022 NS NS
Osteoporosis -0.081‡ 0.020 -0.059± 0.022 NS NS
Other CVD -0.045± 0.017 NS NS NS NS
R-square of model 0.683 0.016 0.509 0.023 0.340 0.023
Notes: ‡P , 0.001; ±P , 0.01; *P , 0.05; goodness of model fit: P-values listed in parentheses; estimator = MLR; 127 free parameters; Chi-square = 248.122 (df = 121) with 
P-value , 0.0001; CFI = 0.973; RMSEA = 0.031; 90% CI = (0.026, 0.037); SRMR = 0.032.
Abbreviations: CVD, cardiovascular disease; NS, nonsignificant; SE, standard error; MLR, maximum likelihood with robust standard errors; CFI, comparative fit index; 
RMSEA, root mean square error of approximation; SRMR, standardized root mean square residual.
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Determinants of the more distal generic beliefs are 
presented in Table 4. The more distal generic beliefs were 
predominately influenced by age and disease. Older adults 
and respondents with asthma were more engaged in their 
care compared to responders with hypertension (R2 = 0.037). 
Greater information-seeking tendency was associated with 
female gender, more education, older age, and having asthma 
or other CVD compared to hypertension (R2 = 0.077). 
Internal locus of control was associated with less education 
and nonwhite race (R2 = 0.014). Better self-rated health was 
associated with higher income, older age, and a lower like-
lihood of other CVD or diabetes compared to hypertension 
(R2 = 0.121). Finally, better mental health was associated 
with older age and higher income (R2 = 0.107).
Discussion
Over the past 40 years, research on the determinants of 
medication adherence has gradually shifted from a focus 
on generic health beliefs to beliefs specific to a treatment 
and a disease. The Necessity-Concerns Framework6 and 
Proximal–Distal Continuum9 are two frameworks that hold 
that medication adherence is more powerfully explained by 
treatment-specific than by generic beliefs. Generic beliefs, in 
turn, are useful in understanding the determinants of disease-
specific beliefs. To the best of the authors’ knowledge, this is 
the first study that has concurrently modeled the predictors 
of treatment-specific, proximal medication beliefs: perceived 
need for medications, perceived medication concerns, and 
perceived medication affordability.
Numerous hypotheses were tested in the SEM model-
ing of the proximal–distal continuum. However, only a few 
components of the proximal–distal continuum consistently 
emerged as statistically-significant predictors with relatively 
large path coefficients (perceived disease severity, patient 
knowledge, perceived side-effect immunity, perceived 
value of nutraceuticals, and patient engagement). These 
five variables are also the most clinically mutable beliefs 
and skills in the proximal–distal continuum. Because so 
few studies have studied the determinants of treatment-
specific beliefs, we contextualize these results largely with 
past research on medication adherence and discuss their 
implications for adherence communication and adherence 
interventions.
Three of the intermediate, independent variables – 
perceived disease severity, knowledge about the index 
medication, and perceived value of nutraceuticals – were 
significantly associated with all three proximal adherence 
drivers. Perceived disease severity – or the potential for a 
condition to cause physical, mental or psychosocial harm – 
is a significant component of most social-cognitive models 
of medication taking.2 Consistent with past research,18–21,76,77 
perceived disease severity was a significant predictor of the 










Perceived value of 
nutraceuticals
Standardized β SE Standardized β SE Standardized β SE Standardized β SE
Patient engagement 0.254‡ 0.029 0.521‡ 0.023 0.259‡ 0.030 -0.415‡ 0.026
Health information seeking 0.122‡ 0.028 0.325‡ 0.026 -0.242‡ 0.030 0.126‡ 0.029
Internal health locus of control NS NS 0.062± 0.024 NS NS 0.209‡ 0.026
Self-rated health -0.262‡ 0.030 NS NS NS NS 0.100‡ 0.028
Mental health -0.112‡ 0.030 0.047* 0.021 0.119‡ 0.029 NS NS
Age NS NS NS NS NS NS -0.084± 0.025
Female NS NS NS NS -0.111‡ 0.027 NS NS
White race NS NS NS NS NS NS -0.053* 0.025
Education -0.105‡ 0.027 NS NS 0.126‡ 0.028 -0.083± 0.028
Income NS NS NS NS NS NS -0.122‡ 0.029
Asthma -0.074* 0.031 NS NS NS NS 0.060* 0.026
Diabetes 0.130‡ 0.026 NS NS NS NS NS NS
Lipid NS NS NS NS NS NS NS NS
Osteoporosis -0.103‡ 0.029 NS NS NS NS 0.128‡ 0.025
Other CVD 0.094‡ 0.026 NS NS NS NS NS NS
R square for model 0.251 0.023 0.477 0.025 0.151 0.020 0.286 0.024
Notes: ‡P , 0.001; ±P , 0.01; *P , 0.05; goodness of model fit: P-values listed in parentheses; estimator = MLR; 127 free parameters; Chi-square = 248.122 (df = 121) with 
P-value , 0.0001; CFI = 0.973; RMSEA = 0.031; 90% CI = (0.026, 0.037); SRMR = 0.032.
Abbreviations: CVD, cardiovascular disease; NS, nonsignificant; SE, standard error; MLR, maximum likelihood with robust standard errors; CFI, comparative fit index; 
RMSEA, root mean square error of approximation; SRMR, standardized root mean square residual.
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three proximal treatment beliefs, but particularly of perceived 
need for medications. Patients who perceive their disease 
to be more severe may appreciate the long-term value of 
therapy, thus strengthening their intrinsic commitment to 
medication taking. Patients who perceive their disease to be 
more severe might be taking multiple medications, thereby 
making medications less affordable and raising concerns 
about medication side effects and medication interactions. 
Greater disease severity has been directly linked to improved 
medication adherence in numerous studies78–82 including 
a meta-analysis.83 Lack of perceived disease severity was 
cited as a reason for both medication nonfulfillment and 
nonpersistence in a study of US adults with chronic disease.62 
Patients need to understand the severity of their condition 
in order to internalize the rationale for therapy and develop 
ego commitment to the medication. Health care providers 
are uniquely qualified to convey to patients the potential 
severity of their conditions as well as short- and long-term 
consequences of undertreated or untreated chronic disease. 
Educational-based adherence interventions should explicitly 
address disease severity as a content area and assess patient 
understanding using well-established, patient-centered com-
munication techniques.
In this study, patients with more knowledge about the 
index medication had significantly greater commitment to 
(need for) the medication, fewer medication concerns, and 
greater perceived medication affordability. The largest effect 
was observed for perceived need for the medication. Patient 
knowledge has been positively linked with medication adher-
ence in many studies.51,84–92 Information/knowledge is one of 
the troika of adherence drivers in two adherence conceptual 
frameworks – the Information-Motivation-Behavioral Skills 
model7 and the Information-Motivation-Strategy model.8 
Lack of knowledge about the disease and/or prescribed 
therapy has been reported by patients as a reason for medica-
tion nonfulfillment or nonpersistence.93–96
Both qualitative97–101 and quantitative102–106 research has 
revealed that many patients lack knowledge about their diag-
nosed conditions, the potential severity of their conditions, 
and the consequences of lack of treatment. Patients also fre-
quently report a lack of information about newly prescribed 
medications.43,102,103,107–116 Without sufficient knowledge about 
their condition, its potential severity, and the rationale for the 
prescribed medication, many patients may find it difficult to 
identify with (be ego involved with) the diagnosis and therapy 
and to accept therapy with a sense of autonomous choice. 
When uncertainty and ambiguity are high, people tend to 
pessimistically evaluate the risk and benefits of therapy.117 
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Thus, lack of information and knowledge about the diagnosed 
condition and the prescribed therapy can exacerbate patients’ 
uncertainty and ambivalence about prescription medications 
and can inhibit their internalization of their condition as 
chronic in nature.
Past educational/knowledge-based adherence inter-
ventions have tended to have small effect sizes.118 This 
finding may be due to education and knowledge being 
operationalized and delivered differently across studies (eg, 
as disease knowledge, risk-factor knowledge, medication 
knowledge, and/or regimen knowledge) and the possibility 
that knowledge may more powerfully predict the proximal 
determinants of adherence –perceived need, concerns, and 
affordability – than adherence per se. Further, few adher-
ence interventions have involved patients in the design and 
content of the intervention. Future adherence interventions 
should be truly patient-centered and involve patients a priori 
in determining what is needed, how much is needed, for 
how long, and via what channel. It is plausible that what 
newly diagnosed heart failure patients require in terms of 
information may be quantitatively and qualitatively different 
from what breast cancer patients newly prescribed adjuvant 
hormonal therapy need and prefer. Future adherence inter-
ventions should conceptualize knowledge in a multifactorial 
sense and deliver it longitudinally via a variety of channels 
and settings.119
Many past knowledge-based adherence interventions 
have been of short duration with only a handful or less of 
interventional touch points. Future adherence interventions 
should focus on the first two months of therapy, when the 
risk of nonpersistence is greatest. Multiple interventional 
touch points can reinforce learning and help minimize 
uncertainty. Disease knowledge (etiology, severity, course, 
and sequelae) and medication knowledge (rationale, dura-
tion of therapy, alternative therapies, risks and benefits, and 
consequences of nonadherence) need to be communicated 
in health–literacy appropriate ways. Such knowledge could 
be delivered with patient-centered decision aids or tools 
that attempt to present unbiased and complete information 
about the potential benefits and downsides of treatment 
choices.120 The promise of patient-centered decision aids 
for prescription medications lies in the hope that, through 
their use, providers will be preparing patients for treatment 
and involving them in the treatment process. Patients may 
more readily and consistently accept treatment if they feel 
the decision to start therapy is their choice rather than the 
provider’s directive.121 Finally, it is important to underscore 
the difference between information/knowledge and patient 
understanding. Patients can only do what they understand.8 
Numerous patient-centered techniques are available to gauge 
patient understanding, such as “teach-back,”122 “ask-tell-
ask,”123 and “elicit-provide-elicit.”124 These techniques could 
not only be used in adherence interventions but in routine 
clinical practice as well at the time of prescribing. In one 
study, physicians trained in ask-tell-ask were able to success-
fully employ the technique without statistically increasing 
the median visit length.125
A novel finding from this study is that respondents who 
placed more value on nutraceuticals (vitamins, supplements, 
and minerals) had lower perceived need for medications, 
more medication concerns, and less perceived medication 
affordability. Some adults believe over-the-counter and 
herbal remedies are less risky than prescription medications 
and that they are natural, safe, familiar, and can be used 
with less risk.126–128 Gascon100 found that there was greater 
confidence in herbal or natural remedies than in prescription 
medicines to treat hypertension. Other research has found 
use of complementary and alternative medicine (CAM) to 
be associated with suboptimal medication-effectiveness 
beliefs129 and worse medication adherence.130–134 Favorable 
attitude toward CAM has been reported to be associated 
with worse adherence intentions.135 Thus, some adults may 
be substituting pharmaceuticals with nutraceuticals.
An uncertainty lens helps to explain why some patients 
migrate toward nutraceuticals and alternative medicine for 
the self-management of chronic disease – they are viewed as 
doing something good for oneself (“natural” remedies) and 
as actions involving little risk and little threat to the status 
quo. Internet website and print communications abound with 
advertisements that claim to treat or cure chronic disease 
naturally. Past research has shown that providers are not 
proactive in discussing nutraceuticals and CAM,131,136 and 
that patients do not proactively disclose their nutraceutical 
and CAM use to their providers.137,138 Physicians, pharma-
cists, and interventionists should proactively address use of 
nutraceuticals with patients and communicate their relative 
clinical efficacy for the treatment of chronic disease com-
pared to prescription medications. Future research should 
better understand the role of nutraceuticals specifically, and 
CAM generally, in patients’ adherence decisions.
Perceived side-effect immunity was a signif icant 
 predictor of perceived need and perceived concerns but not 
affordability. Perceived side-effect immunity was the most 
important predictor of perceived medication concerns. Other 
research has linked perceived sensitivity to side effects with 
enhanced medication concerns.6,77 Fear of side effects and 
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perceived side-effect susceptibility have been documented 
in the literature as reasons for medication nonadherence 
 (nonfulfillment or nonpersistence)62,139–145 and noncompli-
ance (usage deviations).146 Little is known about how or why 
patients come to feel susceptible to side effects. However, 
research has documented that patients report significant unmet 
need for side-effect information.110,147–149 Physicians express 
concern that disclosure of side-effect information will increase 
patients’ report and/or experience of side effects through the 
effect of suggestability.150–154 However, extant research has 
refuted this line of reasoning: side-effect forewarning through 
verbal or written information has not been shown to increase 
reports of side effects.155–161 On the contrary, patients have 
relayed that, armed with information about side effects, they 
would be less likely to become alarmed should a side effect 
occur and would have fewer concerns about them.162–164 In 
one study, patients reported that detailed disclosure about side 
effects would make them feel more confident in the physician 
(94%), more likely to adhere to treatment (91%), and more 
confident in the medication (82%).150
Unaddressed medication concerns and fear of side effects 
can intensify patients’ uncertainty especially when the poten-
tial benefits of medication therapy have not been appropri-
ately communicated and when potential benefits do not occur 
immediately, as with most asymptomatic chronic conditions. 
Providers should disclose common side effects and create a 
plan with patients that addresses what they should do should 
a side effect occur.165 Such collaborative communication 
behaviors are consistent with patient-centered care and shared 
decision making. Adherence interventionists can employ 
patient-centered decision aids to communicate both the pros 
and cons of treatment in a balanced manner.
Our measure of patient engagement assessed patient 
trust in their provider and patient involvement in their care. 
In this study, patient engagement was a significant predictor 
of six of the seven outcomes (all but perceived medication 
affordability). Patients who were more engaged in their care 
had a greater perceived need for medications, fewer medi-
cation concerns, perceived their disease to be more severe, 
had more knowledge about the index medication, felt more 
immune to side effects, and valued nutraceuticals less. The 
greatest impact was on prescription-medication knowledge. 
In women with osteoporosis, Schousboe et al20 also found 
patient engagement to be significantly related to greater per-
ceived need for medications and fewer medication concerns. 
Two other studies reported patient trust to be associated with 
better medication beliefs,21,166 a finding similar to our observed 
results. Both patient trust167–171 and patient involvement172–174 
have been demonstrated in past research to be associated with 
improved medication adherence. Two recent meta-analyses 
concluded that better physician–patient collaboration175 and 
better physician communication176 significantly influence 
medication adherence.
Patient engagement is a key foundational element of 
patient-centered care and shared decision making. Past 
research has shown that patients can be coached to be more 
proactively involved in their care.177–185 Involving patients 
in medication-therapy decision making may increase their 
intrinsic motivation and ego involvement in treatment. 
A simple way to engage patients is to ask whether they are 
ready to commit to therapy. Patients’ expression of uncer-
tainty or ambivalence is a marker for unresolved concerns or 
unmet information needs. Patient-centered decision aids for 
prescription medications may be a cost- and time-effective 
way of increasing patient engagement in their treatment in 
both clinical practice and in adherence interventions.
Although numerous hypotheses were tested in the SEM 
modeling of the proximal–distal continuum, none of the 
observed results were anomalous. In the vast majority of 
findings, coefficient signs were in the expected direction. 
As a predictor variable, the multi-item scale assessing 
health-information seeking yielded three results that could 
have plausibly been either positive or negative. Patients 
with greater health–information seeking tendencies had less 
perceived need for medications (Table 2), more perceived 
medication concerns, (Table 2), and less perceived immunity 
to side effects (Table 3). While health-information seeking 
was significantly and positively related to greater patient 
knowledge (Table 3), it is possible that health-information 
seeking could generate negative or even conflicting informa-
tion, which could then dampen perceived need, elevate medi-
cation concerns, and elevate susceptibility to side effects.
Study strengths and limitations
There are both strengths and limitations to the study. In terms 
of strengths, use of the proximal–distal continuum was based 
upon both conceptual and empirical learning accumulated 
over the past 40 years. A large, internet-based panel of adults 
with chronic disease was accessed with representation from 
47 of the 50 US states. Most of the multi-item scales were 
highly internally consistent (range of Cronbach’s alpha of 
0.76 to 0.97, median = 0.91). We had a large sample size 
(n = 1072) upon which to test the SEM model.
In terms of limitations, the survey contact rate (26.5%) 
was low. Survey noncontact analysis indicated that persons 
aged 55 years and older, whites, and those with at least a 
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college degree were more likely to be successfully contacted 
than their respective counterparts.9 The obtained internet-
based sample was slightly underrepresented by adults with 
income less than $25,000 annually compared to the US 
adult population.186 Also, relative to the US adult population 
aged 25 years and older,187,188 the obtained sample had an 
underrepresentation of adults with less than a high-school 
education, an overrepresentation of adults with at least a 
college degree, and overrepresentation of whites. Because 
of these demographic differences between the obtained 
sample and the US general adult population, generalizabil-
ity of our results to the broader US population may not be 
appropriate. An Internet panel was used, which also may 
limit generalizability. The study was cross sectional. As a 
result of the cross-sectional design, no inferences regarding 
causality of the elements of the proximal–distal continuum 
can be made. The study involved adults with self-identified 
chronic disease. None of the six study conditions were 
substantiated with medical records. On the other hand, 
a well-defined, chronic disease panel was accessed and the 
six conditions were reverified using a separate, independent 
screener than was used to enroll the Chronic Illness Panel. 
Only six conditions were studied, although they are highly 
prevalent in the US adult population. No psychiatric condi-
tions were studied. The array of adherence drivers tested in 
the proximal–distal continuum was not exhaustive of the 
200 putative adherence determinants.189 We did not study 
some adherence determinants included in other research, 
such as self-efficacy, social support, symptom severity, 
the experience of side effects, side-effect severity, length 
of time with the diagnosis, and length of time in treatment 
with prescription-medication therapy. We only tested the 
proximal–distal continuum and did not test alternative 
theoretical models of adherence drivers.
Conclusion
For decades now, nonadherence has been among the most 
 significant problems facing medical practice.190  Nonadherence 
is a psychosocial marker that issues important to patients 
were not addressed – that patients have unvoiced uncertain-
ties and ambivalence about their condition and prescribed 
therapy. In clinical practice, a shroud of silence envelopes 
the topic of medication adherence: physicians often do not 
proactively ask about adherence and patients frequently do 
not tell them when they fail to fill a new prescription or stop 
therapy on their own.9 Thus, patients are largely alone with 
their doubts and uncertainties. For long-term medication 
adherence, patients need to autonomously and intrinsically 
commit to therapy and this is more likely to occur when they 
are informed (about disease knowledge, disease severity, 
medication knowledge and rationale, consequences of non-
adherence, and side effects), understand, and are motivated 
(engaged in their care, perceive a need for medication, and 
believe the benefits outweigh the risks). In short, intuitively 
patient-centered strategies are needed to help patients to 
know what their condition is, why the medication is needed, 
how the prescribed therapy may help, and how the benefits 
may outweigh the risks.
Testing the proximal–distal continuum of adherence driv-
ers sheds light on specific areas where adherence dialogue 
and enhancement could focus. Our results can help to inform 
the design of future adherence interventions, as well as the 
content of patient-education materials and adherence reminder 
letters. An important learning from testing the proximal–distal 
continuum is that future adherence interventions need to move 
from manipulating single adherence barriers to interceding in a 
multidimensional space. Results also suggest that intervening 
along the etiological continuum of patient beliefs, states, and 
skills may more optimally improve adherence than interven-
ing in a single causal space. Interventions that focus on distal 
beliefs, states, and skills should be deprioritized. Instead of 
assuming a one-size-fit-all design, future adherence interven-
tions should target persons who are deficit in the proximal 
determinants of adherence: perceived need for medications, 
perceived medication concerns, and perceived medication 
affordability. In addition, it should be possible to target patients 
or tailor interventions using the most important sociomedical 
predictors identified in this study: perceived disease severity, 
patient knowledge, perceived side-effect immunity, perceived 
value of nutraceuticals, and patient engagement.
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